Further studies exploring the intricate interplay between HMGA1 and FKBP1A could potentially lead to novel therapeutic strategies targeting this signaling pathway to improve the effectiveness of rapamycin-based treatments in ESCC and possibly other cancer types as well. The gene discussed is HMGA1; the disease is cancer.